The abstract is read at the publisher; the summary is JClub's.
Mucins in the tumour microenvironment trigger disassembly of mPEG-polyester micellar nanoparticles into unimers, enabling a mucin-responsive paclitaxel nanomedicine to deliver 3.9-fold more tumour cells in pancreatic mouse tumours.
- Why it matters: Solid-tumour nanomedicines often fail to reach tumour cells because mucins form a glycosylated barrier enriched in the tumour microenvironment.
- What they did: The team engineered a mucin-responsive, paclitaxel-conjugated nanomedicine (mrPNM) whose unimers can escape mucin binding, then compared it after intravenous dosing to a mucin-nonresponsive nanomedicine and albumin in a pancreatic mouse tumour model.
- The result: mrPNM showed markedly deeper penetration and 3.9-fold and 1.5-fold increases in tumour cell delivery versus the mucin-nonresponsive nanomedicine and albumin, respectively, and produced superior tumour growth inhibition across three solid tumour models versus both controls and Abraxane.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.